Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Guadecitabine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Astex trials of guadecitabine for leukaemia fail to meet primary end point
    Astex trials of guadecitabine for leukaemia fail to meet primary end point

    15 Oct 2020

    // CLINICALTRIALSAENA

    https://www.clinicaltrialsarena.com/news/astex-leukaemia-trial-fail/

    CLINICALTRIALSAENA
    15 Oct 2020
    Share Share
    Otsuka's guadecitabine flunks 2 more late-phase cancer trials
    Otsuka's guadecitabine flunks 2 more late-phase cancer trials

    15 Oct 2020

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/otsuka-s-guadecitabine-flunks-2-more-late-phase-cancer-trials

    Nick Paul Taylor FIERCE BIOTECH
    15 Oct 2020
    Share Share
    Otsuka scores PhIII win for another Astex drug; GSK expands Nucala use in asthma
    Otsuka scores PhIII win for another Astex drug; GSK expands Nucala use in asthma

    07 Jun 2019

    // Amber Tong ENDPTS

    https://endpts.com/otsuka-scores-phiii-win-for-another-astex-drug-gsk-expands-nucala-use-in-asthma/

    Amber Tong ENDPTS
    07 Jun 2019
    Share Share
    Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for AML
    Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for AML

    01 Aug 2018

    // John Carroll ENDPTS

    https://endpts.com/otsukas-886m-plus-drug-just-flopped-in-its-first-crucial-phiii-trial-for-frontline-aml/

    John Carroll ENDPTS
    01 Aug 2018
    Share Share
    Astex Pharms, Otsuka Announce Results of Ph 3 ASTRAL-1 Study of Guadecitabine
    Astex Pharms, Otsuka Announce Results of Ph 3 ASTRAL-1 Study of Guadecitabine

    31 Jul 2018

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20180730005782/en

    BUSINESSWIRE
    31 Jul 2018
    Share Share